MOYOM Biotech, a Shanghai-based biotechnology company focused on regenerative aesthetic biomaterials, announced on September 28, 2026, that it has completed a new financing round from the Cathay Consumer Co-Creation Fund, which is managed by Cathay Capital. The investment, made for an undisclosed amount, marks an important milestone in the company's development and will support its next phase of global growth. The funding positions MOYOM to accelerate clinical translation, pursue additional regulatory approvals, and expand into overseas markets.
Strategic Investment Backed by Industry Leaders
The Cathay Consumer Co-Creation Fund was jointly established by Cathay Capital, L'Oréal, and the Shanghai Jing'an District Government to foster innovation in beauty, health, and skin science. Cathay Capital has built a global investment ecosystem spanning consumer, healthcare, and technology, with notable investments including Moonshot AI, Momenta, Chime, Ledger, Glovo, and Owkin. Beyond identifying emerging brands, such investment platforms can give strategic partners earlier access to emerging technologies, supply chain capabilities, and innovation in adjacent industries.
Proprietary Regenerative Biomaterial Platform
Founded in 2018, MOYOM focuses on nanomedical biomaterials and Class III absorbable implantable medical devices, particularly calcium hydroxylapatite, or CaHA, regenerative materials. Its flagship brand, Aphranel®, brings the company's proprietary biomaterials research to market as a new-generation CaHA biostructurer. The product is designed to combine immediate structural support, regenerative stimulation, and complete biodegradation.
Dual Technology Foundation
MOYOM's technology platform is built around two proprietary technologies, ACD-MT® raspberry-shaped through-hole CaHA microspheres and PCD-ETT® physically cross-linked CMC gel technology. Together, these technologies are engineered to deliver structural performance, support regenerative interaction, and enable controlled biodegradation. This dual technology foundation underpins Aphranel® and supports the company's broader research and development pipeline.
Regulatory Milestones in China and Europe
Aphranel® received Class III medical device registration from China's National Medical Products Administration, or NMPA, in February 2025. The product then achieved certification under the European Union Medical Device Regulation, or EU MDR, in May 2026. These approvals establish a regulatory foundation for international expansion and validate the company's quality and safety standards.
Commercial Adoption Across China
Since its commercial launch in May 2025, Aphranel® has been introduced in more than 700 medical aesthetics clinics across China. This rapid adoption demonstrates increasing market demand alongside continued scientific and regulatory progress. The brand is now building a clinical footprint that supports future international growth and deeper engagement with medical aesthetics professionals.
Global Growth Plans
With its proprietary technology platform, key regulatory milestones, and growing market presence, MOYOM is entering a new phase of growth. Leveraging Cathay Capital's global ecosystem, the company plans to accelerate clinical translation, pursue additional regulatory approvals, and expand into overseas markets. MOYOM also intends to continue investing in next-generation regenerative biomaterials and broadening its product portfolio.
The new financing will support MOYOM's efforts to bring biomaterial innovation originating in China to international markets and establish Aphranel® as a science-driven regenerative aesthetics brand with global reach. Cathay Capital's investment reflects growing interest in technologies and biomaterial innovations that could shape the next generation of the beauty and medical aesthetics industry. With a regulatory foundation in both China and Europe and a growing clinical footprint, MOYOM is positioned to advance its international expansion strategy.